Second international consensus guidelines for breast cancer in young women (BCY2)

Breast

Volumn 26, Issue , 2016, Pages 87-99

  Paluch Shimon, Shani ^a   Pagani, Olivia ^b   Partridge, Ann H ^c   Bar Meir, Eran ^d   Fallowfield, Lesley ^e   Fenlon, Deborah ^f   Friedman, Eitan ^a   Gelmon, Karen ^g   Gentilini, Oreste ^h   Geraghty, James ⁱ   Harbeck, Nadia ^j   Higgins, Stephen ^k   Loibl, Sibylle ^l   Moser, Elizabeth ^m   Peccatori, Fedro ⁿ   Raanani, Hila ^a   Kaufman, Bella ^a   Cardoso, Fatima ^m,o  

^a SHEBA MEDICAL CENTER   (Israel)

^b ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND   (Switzerland)

^c HARVARD MEDICAL SCHOOL   (United States)

^d BAR ILAN UNIVERSITY   (Israel)

^e UNIVERSITY OF SUSSEX   (United Kingdom)

^f UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^g BRITISH COLUMBIA CANCER AGENCY   (Canada)

^h SAN RAFFAELE HOSPITAL   (Italy)

ⁱ ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^j UNIVERSITY OF MUNICH   (Germany)

^k ADELAIDE AND MEATH HOSPITAL   (Ireland)

^l SANA KLINIKUM OFFENBACH   (Germany)

^m Champalimaud Cancer Center   (Portugal)

ⁿ EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^o EUROPEAN SCHOOL OF ONCOLOGY   (Italy)

more..

Author keywords

Breast cancer; Consensus; Guidelines; Young women

Indexed keywords

ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; PROTEIN INHIBITOR;

ADJUVANT CHEMOTHERAPY; ADVANCED CANCER; ARTICLE; BONE DISEASE; BONE HEALTH; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RESEARCH; CANCER STAGING; CANCER SURGERY; CARDIOVASCULAR DISEASE; COGNITIVE DEFECT; CONTRACEPTION; DIAGNOSTIC IMAGING; DISEASE ASSOCIATION; EARLY CANCER; EVIDENCE BASED MEDICINE; FAMILY PLANNING; FEMALE; FERTILITY; FOLLOW UP; GENE MUTATION; HEALTH; HORMONAL THERAPY; HUMAN; INFLAMMATORY BREAST CANCER; IRELAND; LIFESTYLE MODIFICATION; METHODOLOGY; OVARIAN PRESERVATION; PRACTICE GUIDELINE; PREGNANCY; PREMENOPAUSE; PRIORITY JOURNAL; SEXUAL DYSFUNCTION; SUPPORT GROUP; TUMOR SUPPRESSOR GENE; ADULT; BREAST TUMOR; CONSENSUS DEVELOPMENT; DISEASE MANAGEMENT;

ADULT; BREAST NEOPLASMS; DISEASE MANAGEMENT; FEMALE; HUMANS; IRELAND;

EID: 84961786676     PISSN: 09609776     EISSN: 15323080     Source Type: Journal    
DOI: 10.1016/j.breast.2015.12.010     Document Type: Article

References (142)

1. Ferlay J., Shin H.R., Bray F., Forman D., Mathers C., Parkin D.M. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer J Int Cancer 2010, 127(12):2893-2917. Epub 2011/02/26.
2. Desantis C., Ma J., Bryan L., Jemal A. Breast cancer statistics. CA Cancer J Clin 2014 Jan-Feb, 64(1):52-62.
3. WHO Women & health 2009.
4. American Cancer Society Breast cancer facts & figures 2013-2014 2013, American Cancer Society, Atlanta.
5. Keegan T.H., DeRouen M.C., Press D.J., Kurian A.W., Clarke C.A. Occurrence of breast cancer subtypes in adolescent and young adult women. Breast Cancer Res 2012, 14(2):R55. Epub 2012/03/29.
6. Collins L.C., Marotti J.D., Gelber S., Cole K., Ruddy K., Kereakoglow S., et al. Pathologic features and molecular phenotype by patient age in a large cohort of young women with breast cancer. Breast Cancer Res Treat 2012, 131(3):1061-1066. Epub 2011/11/15.
7. Azim H.A., Michiels S., Bedard P.L., Singhal S.K., Criscitiello C., Ignatiadis M., et al. Elucidating prognosis and biology of breast cancer arising in young women using gene expression profiling. Clin Cancer Res 2012, 18(5):1341-1351. Epub 2012/01/21.
8. Partridge A.H., Hughes M.E., Ottesen R.A., Wong Y.N., Edge S.B., Theriault R.L., et al. The effect of age on delay in diagnosis and stage of breast cancer. Oncologist 2012, 17(6):775-782. Epub 2012/05/05.
9. Partridge A.H., Gelber S., Piccart-Gebhart M.J., Focant F., Scullion M., Holmes E., et al. Effect of age on breast cancer outcomes in women with human epidermal growth factor receptor 2-positive breast cancer: results from a herceptin adjuvant trial. J Clin Oncol 2013, 31(21):2692-2698. Epub 2013/06/12.
10. Couch F.J., Hart S.N., Sharma P., Toland A.E., Wang X., Miron P., et al. Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer. J Clin Oncol 2015, 33(4):304-311. official journal of the American Society of Clinical Oncology, Epub 2014/12/03.
11. de Sanjose S., Leone M., Berez V., Izquierdo A., Font R., Brunet J.M., et al. Prevalence of BRCA1 and BRCA2 germline mutations in young breast cancer patients: a population-based study. Int J Cancer 2003, 106(4):588-593. Epub 2003/07/08.
12. Kwon J.S., Gutierrez-Barrera A.M., Young D., Sun C.C., Daniels M.S., Lu K.H., et al. Expanding the criteria for BRCA mutation testing in breast cancer survivors. J Clin Oncol 2010, 28(27):4214-4220. Epub 2010/08/25.
13. Robertson L., Hanson H., Seal S., Warren-Perry M., Hughes D., Howell I., et al. BRCA1 testing should be offered to individuals with triple-negative breast cancer diagnosed below 50 years. Br J Cancer 2012, 106(6):1234-1238. Epub 2012/02/16.
14. Howard-Anderson J., Ganz P.A., Bower J.E., Stanton A.L. Quality of life, fertility concerns, and behavioral health outcomes in younger breast cancer survivors: a systematic review. J Natl Cancer Inst 2012, 104(5):386-405. Epub 2012/01/25.
15. Phillips-Salimi C.R., Andrykowski M.A. Physical and mental health status of female adolescent/young adult survivors of breast and gynecological cancer: a national, population-based, case-control study. Support Care Cancer 2013, 21(6):1597-1604. Epub 2013/01/12.
16. Copson E., Maishman T., Gerty S., Eccles B., Stanton L., Cutress R.I., et al. Ethnicity and outcome of young breast cancer patients in the United Kingdom: the POSH study. Br J Cancer 2014, 110(1):230-241. Epub 2013/10/24.
17. Partridge A.H., Ruddy K.J., Barry W.T., Greaney M., Sprunck-Harrild K., Meyer M.E., et al. Young and strong: a randomized trial to evaluate a program for young women with breast cancer. Poster presentation at the 2013 San Antonio breast cancer symposium 2013, Poster OT2-4-02.
18. Cardoso F., Loibl S., Pagani O., Graziottin A., Panizza P., Martincich L., et al. The European Society of Breast Cancer Specialists recommendations for the management of young women with breast cancer. Eur J Cancer 2012, 48(18):3355-3377. Epub 2012/11/03.
19. Partridge A.H., Pagani O., Abulkhair O., Aebi S., Amant F., Azim H.A., et al. First international consensus guidelines for breast cancer in young women (BCY1). Breast 2014, 23(3):209-220. Epub 2014/04/29.
20. Hebert-Croteau N., Brisson J., Latreille J., Rivard M., Abdelaziz N., Martin G. Compliance with consensus recommendations for systemic therapy is associated with improved survival of women with node-negative breast cancer. J Clin Oncol 2004, 22(18):3685-3693. official journal of the American Society of Clinical Oncology, Epub 2004/08/04.
21. Hassett M.J., Hughes M.E., Niland J.C., Ottesen R., Edge S.B., Bookman M.A., et al. Selecting high priority quality measures for breast cancer quality improvement. Med care 2008, 46(8):762-770. Epub 2008/07/31.
22. Guyatt G., Gutterman D., Baumann M.H., Addrizzo-Harris D., Hylek E.M., Phillips B., et al. Grading strength of recommendations and quality of evidence in clinical guidelines: report from an american college of chest physicians task force. Chest 2006, 129(1):174-181. Epub 2006/01/21.
23. Cardoso F., Costa A., Norton L., Cameron D., Cufer T., Fallowfield L., et al. 1st International consensus guidelines for advanced breast cancer (ABC 1). Breast 2012, 21(3):242-252. Epub 2012/03/20.
24. The requirements of a specialist breast unit. Eur J Cancer 2000, 36(18):2288-2293. Epub 2000/11/30.
25. Partridge A.H., Ruddy K.J., Kennedy J., Winer E.P. Model program to improve care for a unique cancer population: young women with breast cancer. J Oncol Pract 2012, 8(5):e105-10. Epub 2013/01/02.
26. Gabitova G., Burke N.J. Improving healthcare empowerment through breast cancer patient navigation: a mixed methods evaluation in a safety-net setting. BMC Health Serv Res 2014, 14:407. Epub 2014/09/23.
27. Ko N.Y., Darnell J.S., Calhoun E., Freund K.M., Wells K.J., Shapiro C.L., et al. Can patient navigation improve receipt of recommended breast cancer care? Evidence from the National Patient Navigation Research Program. J Clin Oncol 2014, 32(25):2758-2764. official journal of the American Society of Clinical Oncology, Epub 2014/07/30.
28. Fiscella K., Whitley E., Hendren S., Raich P., Humiston S., Winters P., et al. Patient navigation for breast and colorectal cancer treatment: a randomized trial. Cancer Epidemiol Biomarkers Prev 2012, 21(10):1673-1681. a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, Epub 2012/10/10.
29. Colleoni M., Anders C.K. Debate: the biology of breast cancer in young women is unique. Oncologist 2013, 18(4):e13-5. Epub 2013/05/02.
30. Loibl S., Jackisch C., Gade S., Untch M., Paepke S., Kuemmel S., et al. Neoadjuvant chemotherapy in the very young 35 years of age or younger. Cancer Res 2012, 72(24 Suppl.):96s.
31. Goldhirsch A., Winer E.P., Coates A.S., Gelber R.D., Piccart-Gebhart M., Thurlimann B., et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol 2013, 24(9):2206-2223. Epub 2013/08/07.
32. Morrow M., Waters J., Morris E. MRI for breast cancer screening, diagnosis, and treatment. Lancet 2011, 378(9805):1804-1811. Epub 2011/11/22.
33. Houssami N., Turner R., Morrow M. Preoperative magnetic resonance imaging in breast cancer: meta-analysis of surgical outcomes. Ann Surg 2013, 257(2):249-255. Epub 2012/11/29.
34. Houssami N., Turner R., Macaskill P., Turnbull L.W., McCready D.R., Tuttle T.M., et al. An individual person data meta-analysis of preoperative magnetic resonance imaging and breast cancer recurrence. J Clin Oncol 2014, 32(5):392-401. Epub 2014/01/08.
35. Sardanelli F., Boetes C., Borisch B., Decker T., Federico M., Gilbert F.J., et al. Magnetic resonance imaging of the breast: recommendations from the EUSOMA working group. Eur J Cancer 2010, 46(8):1296-1316. Epub 2010/03/23.
36. Chiarelli A.M., Prummel M.V., Muradali D., Majpruz V., Horgan M., Carroll J.C., et al. Effectiveness of screening with annual magnetic resonance imaging and mammography: results of the initial screen from the ontario high risk breast screening program. J Clin Oncol 2014, 32(21):2224-2230. official journal of the American Society of Clinical Oncology, Epub 2014/06/18.
37. Schneider K., Zelley K., Nichols K.E., Garber J. Li-Fraumeni syndrome. GeneReviews(R) 1993, Seattle (WA). R.A. Pagon, M.P. Adam, H.H. Ardinger, S.E. Wallace, A. Amemiya, L.J.H. Bean (Eds.).
38. Kajihara M., Goto M., Hirayama Y., Okunishi S., Kaoku S., Konishi E., et al. Effect of the menstrual cycle on background parenchymal enhancement in breast MR imaging. Magnetic Reson Med Sci 2013, 12(1):39-45. MRMS: an official journal of Japan Society of Magnetic Resonance in Medicine, Epub 2013/03/12.
39. McCuaig J.M., Armel S.R., Novokmet A., Ginsburg O.M., Demsky R., Narod S.A., et al. Routine TP53 testing for breast cancer under age 30: ready for prime time?. Fam Cancer 2012, 11(4):607-613. Epub 2012/08/02.
40. Mester J.L., Moore R.A., Eng C. PTEN germline mutations in patients initially tested for other hereditary cancer syndromes: would use of risk assessment tools reduce genetic testing?. Oncologist 2013, 18(10):1083-1090. Epub 2013/09/17.
41. Bantema-Joppe E.J., de Munck L., Visser O., Willemse P.H., Langendijk J.A., Siesling S., et al. Early-stage young breast cancer patients: impact of local treatment on survival. Int J Radiat Oncol Biol Phys 2011, 81(4):e553-9. Epub 2011/05/24.
42. Botteri E., Bagnardi V., Rotmensz N., Gentilini O., Disalvatore D., Bazolli B., et al. Analysis of local and regional recurrences in breast cancer after conservative surgery. Ann Oncol 2010, 21(4):723-728. Epub 2009/10/17.
43. Vila J., Gandini S., Gentilini O. Overall survival according to type of surgery in young (
44. Niemeyer M., Paepke S., Schmid R., Plattner B., Muller D., Kiechle M. Extended indications for nipple-sparing mastectomy. Breast J 2011, 17(3):296-299. Epub 2011/04/01.
45. Chung A.P., Sacchini V. Nipple-sparing mastectomy: where are we now?. Surg Oncol 2008, 17(4):261-266. Epub 2008/05/06.
46. Ashworth A., Kong W., Whelan T., Mackillop W.J. A population-based study of the fractionation of postlumpectomy breast radiation therapy. Int J Radiat Oncol Biol Phys 2013, 86(1):51-57. Epub 2013/02/26.
47. Paik S., Shak S., Tang G., Kim C., Baker J., Cronin M., et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004, 351(27):2817-2826. Epub 2004/12/14.
48. Buyse M., Loi S., van't Veer L., Viale G., Delorenzi M., Glas A.M., et al. Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst 2006, 98(17):1183-1192. Epub 2006/09/07.
49. Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, et al. Prospective validation of a 21-gene expression assay in breast cancer. N Engl J Med 2015 Nov 19, 373(21):2005-2014.
50. Iwata H., Masuda N., Sagara Y., Kinoshita T., Nakamura S., Yanagita Y., et al. Analysis of Ki-67 expression with neoadjuvant anastrozole or tamoxifen in patients receiving goserelin for premenopausal breast cancer. Cancer 2013, 119(4):704-713. Epub 2012/09/14.
51. NCCN 2015.
52. Davies C., Godwin J., Gray R., Clarke M., Cutter D., et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 2011, 378(9793):771-784. Early Breast Cancer Trialists' Collaborative G, Epub 2011/08/02.
53. Pagani O., Regan M.M., Walley B.A., Fleming G.F., Colleoni M., Lang I., et al. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med 2014, 371(2):107-118. Epub 2014/06/03.
54. Francis P.A., Regan M.M., Fleming G.F. Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med 2015, 372(17):1673. Epub 2015/04/23.
55. Gnant M., Mlineritsch B., Stoeger H., Luschin-Ebengreuth G., Knauer M., Moik M., et al. Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12. Ann Oncol 2015, 26(2):313-320. official journal of the European Society for Medical Oncology/ESMO, Epub 2014/11/19.
56. Castiglione-Gertsch M., O'Neill A., Price K.N., Goldhirsch A., Coates A.S., et al. Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomized trial. J Natl Cancer Inst 2003, 95(24):1833-1846. International Breast Cancer Study G, Epub 2003/12/18.
57. Davidson N.E., O'Neill A.M., Vukov A.M., Osborne C.K., Martino S., White D.R., et al. Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: results from INT 0101 (E5188). J Clin Oncol 2005, 23(25):5973-5982. official journal of the American Society of Clinical Oncology, Epub 2005/08/10.
58. Cuzick J., Ambroisine L., Davidson N., Jakesz R., Kaufmann M., et al. Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials. Lancet 2007, 369(9574):1711-1723. Group LH-aiEBCO, Epub 2007/05/22.
59. Goel S., Sharma R., Hamilton A., Beith J. LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women. Cochrane Database Syst Rev 2009, (4):CD004562. Epub 2009/10/13.
60. Pagani O., Regan M.M., Francis P.A. Exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med 2014, 371(14):1358-1359. Text, Investigators S, International Breast Cancer Study G, Epub 2014/10/02.
61. Davies C., Pan H., Godwin J., Gray R., Arriagada R., Raina V., et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 2013, 381(9869):805-816. Epub 2012/12/12.
62. Gray R.G., Rea D., Handley K., Bowden S.J., Perry P., Earl H.M., et al. aTTom: long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6953 women with early breast cancer. J Clin Oncol 2013, 31. 2013 (suppl; abstr 5).
63. Goss P.E., Ingle J.N., Martino S., Robert N.J., Muss H.B., Livingston R.B., et al. Impact of premenopausal status at breast cancer diagnosis in women entered on the placebo-controlled NCIC CTG MA17 trial of extended adjuvant letrozole. Ann Oncol 2013, 24(2):355-361. official journal of the European Society for Medical Oncology/ESMO, Epub 2012/10/03.
64. Henry N.L., Xia R., Banerjee M., Gersch C., McConnell D., Giacherio D., et al. Predictors of recovery of ovarian function during aromatase inhibitor therapy. Ann Oncol 2013, 24(8):2011-2016. official journal of the European Society for Medical Oncology/ESMO, Epub 2013/04/25.
65. Meirow D., Nugent D. The effects of radiotherapy and chemotherapy on female reproduction. Hum Reprod Update 2001, 7(6):535-543. Epub 2001/12/01.
66. Carlson R.W., Theriault R., Schurman C.M., Rivera E., Chung C.T., Phan S.C., et al. Phase II trial of anastrozole plus goserelin in the treatment of hormone receptor-positive, metastatic carcinoma of the breast in premenopausal women. J Clin Oncol 2010, 28(25):3917-3921. official journal of the American Society of Clinical Oncology, Epub 2010/08/04.
67. Bellet M., GK, Francis P.A., et al. Estrogen levels in premenopausal (prem) patients (pts) with hormone-receptor positive (HR+) early breast cancer (BC) receiving adjuvant triptorelin (Trip) plus exemestane (E) or tamoxifen (T) in the SOFT trial: SOFT-EST substudy. J Clin Oncol 2014, 32(5s). (suppl; abstr 585).
68. Dowsett M., Folkerd E. Deficits in plasma oestradiol measurement in studies and management of breast cancer. Breast Cancer Res BCR 2005, 7(1):1-4. Epub 2005/01/12.
69. Aydiner A., Kilic L., Yildiz I., Keskin S., Sen F., Kucucuk S., et al. Two different formulations with equivalent effect? Comparison of serum estradiol suppression with monthly goserelin and trimonthly leuprolide in breast cancer patients. Med Oncol 2013, 30(1):354. Epub 2013/01/01.
70. Cluze C., Rey D., Huiart L., BenDiane M.K., Bouhnik A.D., Berenger C., et al. Adjuvant endocrine therapy with tamoxifen in young women with breast cancer: determinants of interruptions vary over time. Ann Oncol 2012, 23(4):882-890. official journal of the European Society for Medical Oncology/ESMO, Epub 2011/07/27.
71. Llarena N.C., Estevez S.L., Tucker S.L., Jeruss J.S. Impact of fertility concerns on tamoxifen initiation and persistence. J Natl Cancer Inst 2015, 107(10). Epub 2015/08/27.
72. Partridge A.H., LaFountain A., Mayer E., Taylor B.S., Winer E., Asnis-Alibozek A. Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer. J Clin Oncol 2008, 26(4):556-562. official journal of the American Society of Clinical Oncology, Epub 2008/01/09.
73. Tevaarwerk A.J., Wang M., Zhao F., Fetting J.H., Cella D., Wagner L.I., et al. Phase III comparison of tamoxifen versus tamoxifen plus ovarian function suppression in premenopausal women with node-negative, hormone receptor-positive breast cancer (E-3193, INT-0142): a trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2014, 32(35):3948-3958. official journal of the American Society of Clinical Oncology, Epub 2014/10/29.
74. Bernhard, JLW, K. Ribi, et al., Patient-reported endocrine symptoms, sexual functioning, and quality of life (QoL) in the IBCSG TEXT and SOFT trials: adjuvant treatment with exemestane (E) plus ovarian function suppression (OFS) versus tamoxifen (T) plus OFS in premenopausal women with hormone receptorpositive (HR+) early breast cancer (BC), J Clin Oncol 32:19s.
75. Del Mastro L., Boni L., Michelotti A., Gamucci T., Olmeo N., Gori S., et al. Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: a randomized trial. JAMA J Am Med Assoc 2011, 306(3):269-276. Epub 2011/07/21.
76. Moore H.C., Unger J.M., Phillips K.A., Boyle F., Hitre E., Porter D., et al. Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. N Engl J Med 2015, 372(10):923-932. Epub 2015/03/05.
77. Lambertini M., Ceppi M., Poggio F., Peccatori F.A., Azim H.A., Ugolini D., et al. Ovarian suppression using luteinizing hormone-releasing hormone agonists during chemotherapy to preserve ovarian function and fertility of breast cancer patients: a meta-analysis of randomized studies. Ann Oncol 2015, 26(12):2408-2419. official journal of the European Society for Medical Oncology/ESMO, Epub 2015/09/09.
78. Coleman R., Cameron D., Dodwell D., Bell R., Wilson C., Rathbone E., et al. Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial. Lancet Oncol 2014, 15(9):997-1006. Epub 2014/07/19.
79. Valachis A., Polyzos N.P., Coleman R.E., Gnant M., Eidtmann H., Brufsky A.M., et al. Adjuvant therapy with zoledronic acid in patients with breast cancer: a systematic review and meta-analysis. Oncologist 2013, 18(4):353-361. Epub 2013/02/14.
80. Coleman R., Gnant M., Paterson A., Powles T., von Minckwitz G., Pritchard K., et al. Effects of bisphosphonate treatment on recurrence and cause-specific mortality in women with early breast cancer: a meta-analysis of individual patient data from randomised trials. Presented at the 2013 San Antonio breast cancer symposium 2013, Abstract S4-07.
81. Coleman R.E. Adjuvant bone-targeted therapy to prevent metastasis: lessons from the AZURE study. Curr Opin Support Palliat Care 2012, 6(3):322-329. Epub 2012/07/18.
82. Thurlimann B., Price K.N., Gelber R.D., Holmberg S.B., Crivellari D., Colleoni M., et al. Is chemotherapy necessary for premenopausal women with lower-risk node-positive, endocrine responsive breast cancer? 10-year update of International Breast Cancer Study Group Trial 11-93. Breast Cancer Res Treat 2009, 113(1):137-144. Epub 2008/02/09.
83. Regan M.M., Pagani O., Walley B., Torrisi R., Perez E.A., Francis P., et al. Premenopausal endocrineresponsive early breast cancer: who receives chemotherapy?. Ann Oncol 2008, 19(7):1231-1241. official journal of the European Society for Medical Oncology/ESMO, Epub 2008/03/08.
84. Francis P.A., Regan M.M., Fleming G.F., Lang I., Ciruelos E., Bellet M., et al. Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med 2015, 372(5):436-446. Epub 2014/12/17.
85. Peto R., Davies C., Godwin J., Gray R., Pan H.C., Clarke M., et al. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet 2012, 379(9814):432-444. Epub 2011/12/14.
86. Eiermann W., Pienkowski T., Crown J., Sadeghi S., Martin M., Chan A., et al. Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epidermal growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 trial. J Clin Oncol 2011, 29(29):3877-3884. official journal of the American Society of Clinical Oncology, Epub 2011/09/14.
87. Piccart M.J., Di Leo A., Beauduin M., Vindevoghel A., Michel J., Focan C., et al. Phase III trial comparing two dose levels of epirubicin combined with cyclophosphamide with cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer. J Clin Oncol 2001, 19(12):3103-3110. official journal of the American Society of Clinical Oncology, Epub 2001/06/16.
88. Jones S., Holmes F.A., O'Shaughnessy J., Blum J.L., Vukelja S.J., McIntyre K.J., et al. Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-Year follow-up of US Oncology Research Trial 9735. J Clin Oncol 2009, 27(8):1177-1183. official journal of the American Society of Clinical Oncology, Epub 2009/02/11.
89. Mauri D., Pavlidis N., Ioannidis J.P. Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J Natl Cancer Inst 2005, 97(3):188-194. Epub 2005/02/03.
90. Sikov W.M., Berry D.A., Perou C.M., Singh B., Cirrincione C.T., Tolaney S.M., et al. Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). J Clin Oncol 2015, 33(1):13-21. official journal of the American Society of Clinical Oncology, Epub 2014/08/06.
91. von Minckwitz G., Schneeweiss A., Loibl S., Salat C., Denkert C., Rezai M., et al. Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. Lancet Oncol 2014, 15(7):747-756. Epub 2014/05/06.
92. Ganz P.A., Greendale G.A., Petersen L., Kahn B., Bower J.E. Breast cancer in younger women: reproductive and late health effects of treatment. J Clin Oncol 2003, 21(22):4184-4193. official journal of the American Society of Clinical Oncology, Epub 2003/11/15.
93. Kroenke C.H., Rosner B., Chen W.Y., Kawachi I., Colditz G.A., Holmes M.D. Functional impact of breast cancer by age at diagnosis. J Clin Oncol 2004, 22(10):1849-1856. official journal of the American Society of Clinical Oncology, Epub 2004/05/15.
94. Cardoso F., Costa A., Norton L., Senkus E., Aapro M., Andre F., et al. ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)dagger. Ann Oncol 2014, 25(10):1871-1888. official journal of the European Society for Medical Oncology/ESMO, Epub 2014/09/23.
95. Aebi S., Gelber S., Anderson S.J., Lang I., Robidoux A., Martin M., et al. Chemotherapy for isolated locoregional recurrence of breast cancer (CALOR): a randomised trial. Lancet Oncol 2014, 15(2):156-163. Epub 2014/01/21.
96. Metcalfe K., Gershman S., Ghadirian P., Lynch H.T., Snyder C., Tung N., et al. Contralateral mastectomy and survival after breast cancer in carriers of BRCA1 and BRCA2 mutations: retrospective analysis. BMJ 2014, 348:g226. Epub 2014/02/13.
97. Evans D.G., Ingham S.L., Baildam A., Ross G.L., Lalloo F., Buchan I., et al. Contralateral mastectomy improves survival in women with BRCA1/2-associated breast cancer. Breast Cancer Res Treat 2013, 140(1):135-142. Epub 2013/06/21.
98. van Sprundel T.C., Schmidt M.K., Rookus M.A., Brohet R., van Asperen C.J., Rutgers E.J., et al. Risk reduction of contralateral breast cancer and survival after contralateral prophylactic mastectomy in BRCA1 or BRCA2 mutation carriers. Br J Cancer 2005, 93(3):287-292. Epub 2005/07/30.
99. NICE Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer 2013, (Amended 2015).
100. NCCN Genetic/familial high risk assessment: breast & ovarian V2 2015, 2015.
101. Domchek S.M., Friebel T.M., Garber J.E., Isaacs C., Matloff E., Eeles R., et al. Occult ovarian cancers identified at risk-reducing salpingo-oophorectomy in a prospective cohort of BRCA1/2 mutation carriers. Breast Cancer Res Treat 2010, 124(1):195-203. Epub 2010/02/25.
102. Domchek S.M., Friebel T.M., Singer C.F., Evans D.G., Lynch H.T., Isaacs C., et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. Jama 2010, 304(9):967-975. Epub 2010/09/03.
103. Moyer V.A. Screening for ovarian cancer: U.S. Preventive Services Task Force reaffirmation recommendation statement. Ann Intern Med 2012, 157(12):900-904. Epub 2012/09/12.
104. Iodice S., Barile M., Rotmensz N., Feroce I., Bonanni B., Radice P., et al. Oral contraceptive use and breast or ovarian cancer risk in BRCA1/2 carriers: a meta-analysis. Eur J Cancer 2010, 46(12):2275-2284. Epub 2010/06/12.
105. Gadducci A., Biglia N., Cosio S., Sismondi P., Genazzani A.R. Gynaecologic challenging issues in the management of BRCA mutation carriers: oral contraceptives, prophylactic salpingo-oophorectomy and hormone replacement therapy. Gynecol Endocrinol 2010, 26(8):568-577. Epub 2010/07/17.
106. Cibula D., Zikan M., Dusek L., Majek O. Oral contraceptives and risk of ovarian and breast cancers in BRCA mutation carriers: a meta-analysis. Expert Rev Anticancer Ther 2011, 11(8):1197-1207. Epub 2011/09/16.
107. Balmana J., Diez O., Rubio I.T., Cardoso F. BRCA in breast cancer: ESMO clinical practice guidelines. Ann Oncol 2011, 22(Suppl. 6). vi31-4, Epub 2011/10/20.
108. Tutt A. TNT: a randomized phase III trial of carboplatin compared with docetaxel for patients with metastatic or recurrent locally advanced triple negative or BRCA1/2 breast cancer. San Antonio Breast Cancer Symposium December 2014.
109. Fong P.C., Boss D.S., Yap T.A., Tutt A., Wu P., Mergui-Roelvink M., et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009, 361(2):123-134. Epub 2009/06/26.
110. Yap T.A., Sandhu S.K., Carden C.P., de Bono J.S. Poly(ADP-ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinic. CA Cancer J Clin 2011, 61(1):31-49. Epub 2011/01/06.
111. Khatcheressian J.L., Hurley P., Bantug E., Esserman L.J., Grunfeld E., Halberg F., et al. Breast cancer follow-up and management after primary treatment: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 2013, 31(7):961-965. Epub 2012/11/07.
112. Partridge A.H., Gelber S., Peppercorn J., Sampson E., Knudsen K., Laufer M., et al. Web-based survey of fertility issues in young women with breast cancer. J Clin Oncol 2004, 22(20):4174-4183. Epub 2004/10/16.
113. Loren A.W., Mangu P.B., Beck L.N., Brennan L., Magdalinski A.J., Partridge A.H., et al. Fertility preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 2013, 31(19):2500-2510. official journal of the American Society of Clinical Oncology, Epub 2013/05/30.
114. Blanc B., Lazard A., Estrade J.P., Agostini A., Gurriet B. Contraceptive methods after gynecological and breast cancer. Bull Acad Natl Med 2010, 194(3):521-527. discussion 9-30. Epub 2010/12/22. Contraception apres cancer gynecologique et mammaire.
115. Schwarz E.B., Hess R., Trussell J. Contraception for cancer survivors. J Gen Intern Med 2009, 24(Suppl. 2):S401-S406. Epub 2009/11/05.
116. Rosenberg S.M., Partridge A.H. Premature menopause in young breast cancer: effects on quality of life and treatment interventions. J Thorac Dis 2013, 5(Suppl. 1):S55-S61. Epub 2013/07/03.
117. Loprinzi C.L., Michalak J.C., Quella S.K., O'Fallon J.R., Hatfield A.K., Nelimark R.A., et al. Megestrol acetate for the prevention of hot flashes. N Engl J Med 1994, 331(6):347-352. Epub 1994/08/11.
118. Quella S.K., Loprinzi C.L., Sloan J.A., Vaught N.L., DeKrey W.L., Fischer T., et al. Long term use of megestrol acetate by cancer survivors for the treatment of hot flashes. Cancer 1998, 82(9):1784-1788. Epub 1998/05/12.
119. Bertelli G., Venturini M., Del Mastro L., Bergaglio M., Sismondi P., Biglia N., et al. Intramuscular depot medroxyprogesterone versus oral megestrol for the control of postmenopausal hot flashes in breast cancer patients: a randomized study. Ann Oncol 2002, 13(6):883-888. official journal of the European Society for Medical Oncology/ESMO, Epub 2002/07/19.
120. Rosenberg S.M., Tamimi R.M., Gelber S., Ruddy K.J., Bober S.L., Kereakoglow S., et al. Treatment-related amenorrhea and sexual functioning in young breast cancer survivors. Cancer 2014, 120(15):2264-2271. Epub 2014/06/04.
121. Carter J., Goldfrank D., Schover L.R. Simple strategies for vaginal health promotion in cancer survivors. J Sex Med 2011, 8(2):549-559. Epub 2010/08/21.
122. Dizon D.S., Suzin D., McIlvenna S. Sexual health as a survivorship issue for female cancer survivors. Oncol 2014, 19(2):202-210. Epub 2014/01/08.
123. Azim H.A., Del Mastro L., Scarfone G., Peccatori F.A. Treatment of breast cancer during pregnancy: regimen selection, pregnancy monitoring and more. Breast 2011, 20(1):1-6. Epub 2010/11/30.
124. Kroman N., Jensen M.B., Wohlfahrt J., Ejlertsen B. Pregnancy after treatment of breast cancer-a population-based study on behalf of Danish Breast Cancer Cooperative Group. Acta Oncol 2008, 47(4):545-549. Epub 2008/05/10.
125. Azim H.A., Kroman N., Paesmans M., Gelber S., Rotmensz N., Ameye L., et al. Prognostic impact of pregnancy after breast cancer according to estrogen receptor status: a multicenter retrospective study. J Clin Oncol 2013, 31(1):73-79. Epub 2012/11/22.
126. Pagani O., Partridge A., Korde L., Badve S., Bartlett J., Albain K., et al. Pregnancy after breast cancer: if you wish, ma'am. Breast Cancer Res Treat 2011, 129(2):309-317. Epub 2011/06/24.
127. Theriault R.L., Litton J.K. Pregnancy during or after breast cancer diagnosis: what do we know and what do we need to know?. J Clin Oncol 2013, 31(20):2521-2522. Epub 2013/06/05.
128. Azim H.A., Santoro L., Russell-Edu W., Pentheroudakis G., Pavlidis N., Peccatori F.A. Prognosis of pregnancy-associated breast cancer: a meta-analysis of 30 studies. Cancer Treat Rev 2012, 38(7):834-842. Epub 2012/07/13.
129. Vehmanen L., Elomaa I., Blomqvist C., Saarto T. Tamoxifen treatment after adjuvant chemotherapy has opposite effects on bone mineral density in premenopausal patients depending on menstrual status. J Clin Oncol 2006, 24(4):675-680. Epub 2006/02/01.
130. Sverrisdottir A., Fornander T., Jacobsson H., von Schoultz E., Rutqvist L.E. Bone mineral density among premenopausal women with early breast cancer in a randomized trial of adjuvant endocrine therapy. J Clin Oncol 2004, 22(18):3694-3699. Epub 2004/09/15.
131. Hojan K., Milecki P., Molinska-Glura M., Roszak A., Leszczynski P. Effect of physical activity on bone strength and body composition in breast cancer premenopausal women during endocrine therapy. Eur J Phys Rehabil Med 2013, 49(3):331-339. Epub 2013/02/27.
132. Castellon S.A., Silverman D.H., Ganz P.A. Breast cancer treatment and cognitive functioning: current status and future challenges in assessment. Breast Cancer Res Treat 2005, 92(3):199-206. Epub 2005/09/13.
133. Deprez S., Amant F., Yigit R., Porke K., Verhoeven J., Van den Stock J., et al. Chemotherapy-induced structural changes in cerebral white matter and its correlation with impaired cognitive functioning in breast cancer patients. Hum Brain Mapp 2011, 32(3):480-493. Epub 2010/08/21.
134. Deprez S., Amant F., Smeets A., Peeters R., Leemans A., Van Hecke W., et al. Longitudinal assessment of chemotherapy-induced structural changes in cerebral white matter and its correlation with impaired cognitive functioning. J Clin Oncol 2012, 30(3):274-281. Epub 2011/12/21.
135. Paganini-Hill A., Clark L.J. Preliminary assessment of cognitive function in breast cancer patients treated with tamoxifen. Breast Cancer Res Treat 2000, 64(2):165-176. Epub 2001/02/24.
136. Leining M.G., Gelber S., Rosenberg R., Przypyszny M., Winer E.P., Partridge A.H. Menopausal-type symptoms in young breast cancer survivors. Ann Oncol 2006, 17(12):1777-1782. Epub 2006/09/15.
137. Phillips K.A., Aldridge J., Ribi K., Sun Z., Thompson A., Harvey V., et al. Cognitive function in postmenopausal breast cancer patients one year after completing adjuvant endocrine therapy with letrozole and/or tamoxifen in the BIG 1-98 trial. Breast Cancer Res Treat 2011, 126(1):221-226. Epub 2010/11/04.
138. Phillips K.A., Ribi K., Sun Z., Stephens A., Thompson A., Harvey V., et al. Cognitive function in postmenopausal women receiving adjuvant letrozole or tamoxifen for breast cancer in the BIG 1-98 randomized trial. Breast 2010, 19(5):388-395. Epub 2010/04/14.
139. Nystedt M., Berglund G., Bolund C., Fornander T., Rutqvist L.E. Side effects of adjuvant endocrine treatment in premenopausal breast cancer patients: a prospective randomized study. J Clin Oncol 2003, 21(9):1836-1844. Epub 2003/05/02.
140. Schmid D., Leitzmann M.F. Association between physical activity and mortality among breast cancer and colorectal cancer survivors: a systematic review and meta-analysis. Ann Oncol 2014, 25(7):1293-1311. official journal of the European Society for Medical Oncology/ESMO, Epub 2014/03/20.
141. Loibl S, Schmidt A, Gentilini O, Kaufman B, Kuhl C, Denkert C, et al. Breast cancer diagnosed during pregnancy: adapting recent advances in breast cancer care for pregnant patients. JAMA Oncol 2015, 1(8):1145-1153.
142. Loibl S., Han S.N., von Minckwitz G., Bontenbal M., Ring A., Giermek J., et al. Treatment of breast cancer during pregnancy: an observational study. Lancet Oncol 2012, 13(9):887-896. Epub 2012/08/21.